Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
A double-blind double-dummy study of citalopram comparing infusion versus oral administration.
BACKGROUND This study compares antidepressant efficacy and tolerability of citalopram given either orally or as a slow drop infusion . METHODS Citalopram ( 40 mg/day ) was administered double-blindly as tablets or slow-drop infusion during the first 10 days and then open , orally , up to treatment Day 42 . RESULTS In 60 moderately to severely depressed patients , the Hamilton depression total score ( 17-items ) at baseline was 23.9 and 23.6 in the active infusion ( n = 30 ) and active tablet ( n = 30 ) group , respectively . These scores dropped in both groups to 15.6 and 16.9 on Day 10 , and to 10.3 and 10.2 on Day 42 . Response rates ( delta Hamilton > or = 50 % ) amounted to 33.3 % and 17.9 % on Day 10 , and 66.2 % and 63.3 % on Day 42 , without a relevant group difference in citalopram plasma concentration . CONCLUSION Slow-drop infusion with citalopram shows a similar risk/benefit relationship to oral citalopram . The design of this study allowed us to evaluate pharmacological but not psychological factors which may contribute to response to slow-drop infusion
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .